GlassScriptPhysician profile
Katherine Cox
NPI 1952858011
$6,452.30
in general payments reported to CMS, 2019-2025
32 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,886 · 2022: $1,478 · 2023: $991 · 2024: $607 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,056 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,056.00 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,159.59 | 2021-2025 | |
| Novo Nordisk INC | $1,001.70 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $683.08 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $427.93 | 2021 | |
| Glaxosmithkline, LLC. | $377.92 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $333.78 | 2021-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.12 | 2021-2023 | Jardiance |
| Astellas Pharma US INC | $261.87 | 2022-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $228.08 | 2021-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $197.44 | 2021 | |
| Amarin Pharma, INC. | $192.55 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $168.93 | 2021-2022 | |
| Amgen INC. | $140.52 | 2021-2025 | Repatha, Otezla, Evenity |
| Esperion Therapeutics, INC. | $123.04 | 2021-2022 | |
| Daiichi Sankyo INC. | $93.30 | 2021-2024 | Injectafer |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $92.98 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Janssen Pharmaceuticals, INC | $90.88 | 2021-2022 | |
| Lilly USA, LLC | $79.31 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Sage Therapeutics, LLC | $77.17 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $68.22 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.33 | 2022 | |
| Novartis Pharmaceuticals Corporation | $56.54 | 2022 | |
| Exact Sciences Corporation | $50.26 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Shield Therapeutics INC | $47.00 | 2023-2024 | Accrufer |
| Boston Scientific Corporation | $44.24 | 2023 | Wavewriter Alpha Prime 16 |
| Otsuka America Pharmaceutical, INC. | $24.36 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $21.71 | 2022 | |
| Exeltis, USA INC. | $16.86 | 2023 | Tyblume |
| Phathom Pharmaceuticals, INC. | $15.89 | 2024 | Voquezna |
| Scilex Pharmaceuticals INC. | $15.53 | 2021 | |
| Indivior INC. | $14.63 | 2021 | |
| Allergan, INC. | $14.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.